Company profile
SPRUCE BIOSCIENCES, INC.
NASDAQ:SPRBBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| TILDACERFONT | phase2 | — | 4 | terminated |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (7)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT04457336 | phase2 | terminated | 2020-08-26 | 2024-02-09 | Spruce Biosciences | A Ph2b to Evaluate Clinical Efficacy and Safety of Tildacerfont in Adult CAH |
| NCT04544410 | phase2 | terminated | 2021-02-22 | 2024-10-31 | Spruce Biosciences | A Ph2b to Evaluate Tildacerfont in the Reduction of Glucocorticoid Steroid Doses in Adult CAH |
| NCT05128942 | phase2 | terminated | 2021-12-10 | 2025-01-31 | Spruce Biosciences | A Phase 2 Study to Evaluate the Safety, Efficacy and PK of Tildacerfont in Children Aged 2-17 Years With CAH |
| NCT05370521 | phase2 | terminated | 2022-05-15 | 2023-08-03 | Spruce Biosciences | A Study of Safety and Efficacy of Tildacerfont in Females With Polycystic Ovary Syndrome and Elevated Adrenal Androgens |
| NCT07579910 | phase3 | not_yet_recruiting | 2026-12-01 | 2033-08-01 | Spruce Biosciences | Intracerebroventricular Tralesinidase Alfa in Participants With MPS IIIB (Sanfilippo Syndrome Type B) |
FDA applications (0)
No records yet.